Rhythm Pharmaceuticals, Inc.
RYTM
Κατάταξη σε μετοχές
#2993
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Τιμή μετοχής
$88.46
Τελευταίος συγχρονισμός: 2026-10-21
Κεφαλαιοποίηση
$6.09B
Αλλαγή (1 ημέρα)
-1.93%
Αλλαγή (1 έτος)
-18.97%
Χώρα
US
Εμπόριο Rhythm Pharmaceuticals, Inc. (RYTM)
Κατηγορία
Healthcare
Ιστορικό τιμής μετοχής για την Rhythm Pharmaceuticals, Inc. (RYTM)
Υψηλότερη τιμή κλεισίματος: $89.50 στις 2026-10-01
Χαμηλότερη τιμή κλεισίματος: $24.67 στις 2017-10-01
Χαμηλότερη τιμή κλεισίματος: $24.67 στις 2017-10-01
Ιστορικό τιμής μετοχής της Rhythm Pharmaceuticals, Inc. από 2017 έως 2026
Ετήσια απόδοση τιμής μετοχής
| Έτος | Απόδοση |
|---|---|
| 2026 (TTM) | -8.88% |
| 2025 | 91.54% |
| 2024 | 34.76% |
| 2023 | 48.81% |
| 2022 | 174.77% |
| 2021 | -64.82% |
| 2020 | 24.27% |
| 2019 | -12.59% |
| 2018 | -6.07% |
| 2017 | 0.00% |
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Τιμή μετοχής | Μεταβολή 1Έτ% | Χώρα |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.89 | -3.74% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
